HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

SACATM

This article was originally published in The Rose Sheet

Executive Summary

The Scientific Advisory Committee on Alternative Toxicological Methods recommends as a high priority the further evaluation of three methods designed to replace or refine animal use in toxicology testing. The tests were discussed at a Nov. 30 meeting in Research Triangle Park, NC. The first test is the MCF-7 estrogenic activity cell proliferation assay for cross-laboratory validation studies, which assesses the potential endocrine disruptor activity of a substance. The second nomination goes to the BALB/c 3T3 mouse fibroblast neural red uptake test method for predicting the starting doses of chemical mixtures for acute oral toxicity testing. The third test up for further evaluation is the optimal corneal holder and vehicle for bovine corneal opacity and permeability, which is used to identify potential ocular corrosives. The studies are currently undergoing pre-screening by the National Toxicology Program Interagency Center for the Evaluation of Alternative Toxicological Methods and the Interagency Coordinating Committee on the Validation of Alternative Methods...

You may also be interested in...



QUOTED. 26 February 2020. Mark Leahey.

In an exclusive interview with Medtech Insight, Mark Leahey, president of the Medical Device Manufacturers Association (MDMA), said the previous four Medical Device User Fee negotiations with the US FDA have set a strong foundation for the industry and the next round of negotiations should focus on tweaking past deals that are already in place. See what MDMA's president, Mark Leahey, said about it here.

The Quality Lowdown: On Redeploying Inspectors, API Suppliers Thanks To Coronavirus

US investigators fan out to non-China inspection priorities and Secretary Azar talks supply management; warning letters hit record keeping, investigations and basic GMP compliance.

Mallinckrodt's Opioid Resolution Through Generic Unit Bankruptcy May Be 'Test Case'

Mallinckrodt to pay $1.6bn and place its generics unit in bankruptcy under agreement in principle for US global settlement; six states are not on board, including New York, whose suit is still set to go to trial March 20.

UsernamePublicRestriction

Register

RS014393

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel